{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:54:10Z","timestamp":1790704450310,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["UM1-AI110557"],"award-info":[{"award-number":["UM1-AI110557"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["UM1-AI110557"],"award-info":[{"award-number":["UM1-AI110557"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01-NS080821"],"award-info":[{"award-number":["R01-NS080821"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007270","name":"University of Michigan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007270","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.clim.2016.11.008","type":"journal-article","created":{"date-parts":[[2016,11,23]],"date-time":"2016-11-23T11:47:03Z","timestamp":1479901623000},"page":"10-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"special_numbering":"C","title":["The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases"],"prefix":"10.1016","volume":"175","author":[{"given":"Yang","family":"Mao-Draayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Sarazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Schiopu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2016.11.008_bb0005","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/brain\/awm038","article-title":"Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology","volume":"130","author":"Magliozzi","year":"2007","journal-title":"Brain"},{"issue":"Suppl. 1","key":"10.1016\/j.clim.2016.11.008_bb0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00415-008-1002-8","article-title":"A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis","volume":"255","author":"Weiner","year":"2008","journal-title":"J. Neurol."},{"key":"10.1016\/j.clim.2016.11.008_bb0015","doi-asserted-by":"crossref","first-page":"18889","DOI":"10.1073\/pnas.0806310105","article-title":"Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis","volume":"105","author":"Quintana","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2016.11.008_bb0020","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/WCO.0b013e328346056f","article-title":"Multiple sclerosis as a neurodegenerative disease: pathology, mechanisms and therapeutic implications","volume":"24","author":"Stadelmann","year":"2011","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.clim.2016.11.008_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2010.09.005","article-title":"Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis","volume":"93","author":"Dutta","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.clim.2016.11.008_bb0030","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40263-015-0297-0","article-title":"The direct effects of fingolimod in the central nervous system: implications for relapsing multiple sclerosis","volume":"30","author":"Hunter","year":"2016","journal-title":"CNS Drugs"},{"issue":"0","key":"10.1016\/j.clim.2016.11.008_bb0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jns.2013.02.011","article-title":"Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy","volume":"328","author":"Groves","year":"2013","journal-title":"J. Neurol. Sci."},{"issue":"Suppl. 2","key":"10.1016\/j.clim.2016.11.008_bb0040","first-page":"S15","article-title":"Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis","author":"Tullman","year":"2013","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.clim.2016.11.008_bb0045","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1212\/WNL.58.2.169","article-title":"Disease modifying therapies in multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines","volume":"58","author":"Goodin","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.clim.2016.11.008_bb0050","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1212\/WNL.57.11.1969","article-title":"Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS","volume":"57","author":"Kappos","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.clim.2016.11.008_bb0055","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1212\/01.WNL.0000146958.77317.3E","article-title":"Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study","volume":"63","author":"Panitch","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.clim.2016.11.008_bb0060","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2016.11.008_bb0065","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa052643","article-title":"Oral fingolimod (FTY720) for relapsing multiple sclerosis","volume":"355","author":"Kappos","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2016.11.008_bb0070","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2016.11.008_bb0075","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.semcdb.2004.05.002","article-title":"Physiological and pathological actions of sphingosine 1-phosphate","volume":"15","author":"Hla","year":"2004","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.clim.2016.11.008_bb0080","doi-asserted-by":"crossref","first-page":"21453","DOI":"10.1074\/jbc.C200176200","article-title":"The immune modulator FTY720 targets sphingosine 1-phosphate receptors","volume":"277","author":"Brinkmann","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.clim.2016.11.008_bb0085","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0014-5793(03)01168-2","article-title":"The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2","volume":"554","author":"Paugh","year":"2003","journal-title":"FEBS Lett."},{"key":"10.1016\/j.clim.2016.11.008_bb0090","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1146\/annurev.biochem.78.072407.103733","article-title":"Sphingosine 1-phosphate receptor signaling","volume":"78","author":"Rosen","year":"2009","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.clim.2016.11.008_bb0095","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nri1650","article-title":"Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network","volume":"5","author":"Rosen","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.clim.2016.11.008_bb0100","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/ni1523","article-title":"Natural killer cell trafficking in vivo requires a dedicated sphingosine 1- phosphate receptor","volume":"8","author":"Walzer","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.clim.2016.11.008_bb0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jns.2013.02.011","article-title":"Fingolimod: direct CNS effects of sphingosine 1- phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy","volume":"328","author":"Groves","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.clim.2016.11.008_bb0110","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1055\/s-2007-1019124","article-title":"The immunology of multiple sclerosis","volume":"28","author":"Bar-Or","year":"2008","journal-title":"Semin. Neurol."},{"key":"10.1016\/j.clim.2016.11.008_bb0115","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature02284","article-title":"Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1","volume":"427","author":"Matloubian","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.clim.2016.11.008_bb0120","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1096\/fj.03-0910fje","article-title":"The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors","volume":"18","author":"Graler","year":"2004","journal-title":"FASEB J."},{"key":"10.1016\/j.clim.2016.11.008_bb0125","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.4049\/jimmunol.160.10.5037","article-title":"FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing","volume":"160","author":"Chiba","year":"1998","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.clim.2016.11.008_bb0130","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1474-4422(16)00018-1","article-title":"Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial","volume":"15","author":"Cohen","year":"2016","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.clim.2016.11.008_bb0135","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S1474-4422(16)30192-2","article-title":"Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"15","author":"Kappos","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clim.2016.11.008_bb0140","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1476-5381.2012.02061.x","article-title":"The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate","volume":"167","author":"Gergely","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.clim.2016.11.008_bb0145","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.4049\/jimmunol.1201810","article-title":"Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3","volume":"190","author":"Lewis","year":"2013","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.clim.2016.11.008_bb0150","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3390\/ph5050514","article-title":"Sphingosine 1-phosphate receptor 1 as a useful target for treatment of multiple sclerosis","volume":"5","author":"Chiba","year":"2012","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.clim.2016.11.008_bb0155","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12974-016-0494-x","article-title":"The dual S1PR1\/S1PR5 drug BAF312 (siponimod) attenuates demyelination in organotypic slice cultures","volume":"13","author":"O'Sullivan","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.clim.2016.11.008_bb0160","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0306-4522(02)00791-1","article-title":"Edg-8 receptors are preferentially expressed in oligodendrocyte lineage cells of the rat CNS","volume":"116","author":"Terai","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.clim.2016.11.008_bb0165","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1096\/fj.06-7420com","article-title":"Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration","volume":"21","author":"Novgorodov","year":"2007","journal-title":"FASEB J."},{"key":"10.1016\/j.clim.2016.11.008_bb2000","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1523\/JNEUROSCI.4645-04.2005","article-title":"Edg8\/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival","volume":"25","author":"Jaillard","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.clim.2016.11.008_bb0170","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/glia.20576","article-title":"Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells","volume":"55","author":"Jung","year":"2007","journal-title":"Glia"},{"key":"10.1016\/j.clim.2016.11.008_bb0175","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/glia.10297","article-title":"Characterization of lysophosphatidic acid and sphingosine-1-phosphate-mediated signal transduction in rat cortical oligodendrocytes","volume":"45","author":"Yu","year":"2004","journal-title":"Glia"},{"key":"10.1016\/j.clim.2016.11.008_bb0180","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0014-5793(02)03404-X","article-title":"Embryonic brain expression analysis of lysophospholipid receptor genes suggests roles for s1p(1) in neurogenesis and s1p(1-3) in angiogenesis","volume":"531","author":"McGiffert","year":"2002","journal-title":"FEBS Lett."},{"key":"10.1016\/j.clim.2016.11.008_bb0185","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1046\/j.1471-4159.2003.02219.x","article-title":"Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells","volume":"88","author":"Harada","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.clim.2016.11.008_bb0190","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1128\/MCB.01465-06","article-title":"Involvement of sphingosine-1-phosphate in glutamate secretion in hippocampal neurons","volume":"27","author":"Kajimoto","year":"2007","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.clim.2016.11.008_bb0195","doi-asserted-by":"crossref","first-page":"11113","DOI":"10.1128\/MCB.25.24.11113-11121.2005","article-title":"Essential role for sphingosine kinases in neural and vascular development","volume":"25","author":"Mizugishi","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.clim.2016.11.008_bb0200","doi-asserted-by":"crossref","first-page":"6952","DOI":"10.1523\/JNEUROSCI.17-18-06952.1997","article-title":"Involvement of sphingosine 1-phosphate in nerve growth factor-mediated neuronal survival and differentiation","volume":"17","author":"Edsall","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.clim.2016.11.008_bb0205","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1083\/jcb.200402016","article-title":"Differential transactivation of sphingosine-1-phosphate receptors modulates NGF-induced neurite extension","volume":"166","author":"Toman","year":"2004","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.clim.2016.11.008_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2012.10.004","article-title":"Fingolimod protects cultured cortical neurons against excitotoxic death","volume":"67","author":"Di Menna","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.clim.2016.11.008_bb0215","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1113\/jphysiol.2006.111575","article-title":"Intracellular sphingosine 1-phosphate mediates the increased excitability produced by nerve growth factor in rat sensory neurons","volume":"575","author":"Zhang","year":"2006","journal-title":"J. Physiol."},{"key":"10.1016\/j.clim.2016.11.008_bb2010","series-title":"Oral presentation presented at: 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; September","first-page":"14","article-title":"Efficacy and safety of siponimod in secondary progressive multiple sclerosis - Results of the placebo controlled, double-blind, Phase III EXPAND study","author":"Kappos","year":"2016"},{"key":"10.1016\/j.clim.2016.11.008_bb0220","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.clim.2010.03.428","article-title":"Effects of the novel immunosuppressant FTY720 in a murine rheumatoid arthritis model","volume":"136","author":"Tsunemi","year":"2010","journal-title":"Clin. Immunol."},{"issue":"Supp 10","key":"10.1016\/j.clim.2016.11.008_bb0225","first-page":"S403","article-title":"The selective sphingosine-1- phosphate receptor 1\/5 modulator siponimod (BAF312) shows beneficial effects in patients with active, treatment refractory polymyositis and dermatomyositis: a phase IIa proof-of-concept, double-blind, randomized trial","volume":"910","author":"Danko","year":"2014","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2016.11.008_bb0230","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1136\/ard.2010.134684","article-title":"State-of-the-art: rheumatoid arthritis","volume":"69","author":"McInnes","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2016.11.008_bb0235","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1194\/jlr.M800143-JLR200","article-title":"Specific and overlapping sphingosine-1-phosphate receptor functions in human synoviocytes: impact of TNF-alpha","volume":"49","author":"Zhao","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.clim.2016.11.008_bb0240","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1126\/science.1113640","article-title":"Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients","volume":"309","author":"Schwab","year":"2005","journal-title":"Science"},{"issue":"Supp 10","key":"10.1016\/j.clim.2016.11.008_bb0245","first-page":"S1018","article-title":"The oral S1P lyase inhibitor LX3305 (LX2931) demonstrates favorable safety and potential clinical benefit at 12-weeks in a phase 2 proof-of- concept trial in patients with active rheumatoid arthritis on stable methotrexate therapy","volume":"910","author":"Fleischmann","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2016.11.008_bb0250","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American college of rheumatology preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.clim.2016.11.008_bb0255","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clim.2012.11.001","article-title":"Cytokine inhibition as a strategy for treating systemic lupus erythematosus","volume":"148","author":"Clark","year":"2013","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2016.11.008_bb0260","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3389\/fimmu.2015.00550","article-title":"Pathogenic inflammation and its therapeutic targeting in systemic lupus erythematosus","volume":"6","author":"Gottschalk","year":"2015","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.clim.2016.11.008_bb0265","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/ar3251","article-title":"Abnormalities of T cell signaling in systemic lupus erythematosus","volume":"13","author":"Moulton","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.clim.2016.11.008_bb0270","series-title":"Advances in Immunology","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0065-2776(07)95003-8","article-title":"B-cell self-tolerance in humans","volume":"95","author":"Wardemann","year":"2007"},{"key":"10.1016\/j.clim.2016.11.008_bb0275","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jaut.2014.01.025","article-title":"The diagnosis and classification of polymyositis","volume":"48\u201349","author":"Milisenda","year":"2014","journal-title":"J. Autoimmun."},{"issue":"9388","key":"10.1016\/j.clim.2016.11.008_bb0280","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2016.11.008_bb0285","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1749-6632.2009.05119.x","article-title":"Dermatomyositis and polymyositis","volume":"1184","author":"Mammen","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.clim.2016.11.008_bb0290","series-title":"F1000 Prime Reports","first-page":"109","article-title":"S1P signaling: new therapies and opportunities","volume":"6","author":"Gonzalez-Cabrera","year":"2014"},{"key":"10.1016\/j.clim.2016.11.008_bb0295","series-title":"Innovative Rheumatology","article-title":"Sphingosine-1-phosphate and rheumatoid arthritis: pathological implications and potential therapeutic targets","author":"Zhang","year":"2013"},{"issue":"1","key":"10.1016\/j.clim.2016.11.008_bb0300","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S1521-6616(02)00054-2","article-title":"The immune modulator FYT720 prevents autoimmune diabetes in nonobese diabetic mice\u2606","volume":"107","author":"Yang","year":"2003","journal-title":"Clin. Immunol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661616303138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661616303138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T19:29:24Z","timestamp":1718911764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661616303138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":62,"alternative-id":["S1521661616303138"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2016.11.008","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2016.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}